We are live on ! Find out more
FRTX

Fresh Tracks Therapeutics, Inc. Common Stock

Delisted

FRTX was delisted on the 18th of December, 2023.

64 hedge funds and large institutions have $35.7M invested in Fresh Tracks Therapeutics, Inc. Common Stock in 2014 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 15 increasing their positions, 14 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

373% more call options, than puts

Call options by funds: $175K | Put options by funds: $37K

100% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 5

7% more funds holding

Funds holding: 6064 (+4)

7% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 14

4% less capital invested

Capital invested by funds: $37.2M → $35.7M (-$1.51M)

Holders
64
Holders Change
+4
Holders Change %
+6.67%
% of All Funds
1.71%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
10
Increased
15
Reduced
14
Closed
5
Calls
$175K
Puts
$37K
Net Calls
+$138K
Net Calls Change
+$2K

FRTX Hedge Fund Activity: Q4 2014 in Review

64 of the 3,751 institutional investors tracked by Wall St. Rank reported a position in Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) for Q4 2014, worth a combined $35.7M — down 4.1% from $37.2M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new FRTX positions and 5 closed out — a net gain of 5 holders — while 15 added to existing stakes and 14 trimmed.

The largest buyer was RA Capital Management, adding an estimated $818K. The largest seller was Great Point Partners, cutting an estimated $1.02M.

  • 64 institutional investors held Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) as of Q4 2014, up from 60 in Q3 2014.
  • Funds reported $35.7M of Fresh Tracks Therapeutics, Inc. Common Stock stock for Q4 2014, down 4.1% quarter-over-quarter.
  • 10 funds opened new Fresh Tracks Therapeutics, Inc. Common Stock positions in Q4 2014 and 5 closed out, a net change of +5 holders.
  • The largest Fresh Tracks Therapeutics, Inc. Common Stock buyer in Q4 2014 was RA Capital Management, an estimated $818K added.
  • The largest Fresh Tracks Therapeutics, Inc. Common Stock seller in Q4 2014 was Great Point Partners, an estimated $1.02M sold.

Based on aggregated 13F filings for Q4 2014.